Milestone Scientific Launches CompuFlo Advisor Program
Milestone Scientific announced the launch of the CompuFlo Advisor Program. This strategic initiative is designed to drive mainstream commercial adoption, increase recurring disposable revenue, and generate the clinical data necessary to optimize long-term Medicare reimbursement rates. The program, which commenced on February 1, 2026, targets high-volume interventional pain and anesthesia practices within key Medicare Administrative Contractor jurisdictions, including Novitas, First Coast, Noridian, and Palmetto. These jurisdictions represent a strategic first phase of execution, with infrastructure designed to support phased expansion across additional MAC regions throughout the United States. By engaging Key Opinion Leaders to generate a targeted 1,000-2,000 case submissions in the initial six-month phase, Milestone is executing a structured clinical and reimbursement roadmap to transition CPT code 0777T from Category III to Category I status, that could enhance commercial adoption and long-term revenue visibility.
Trade with 70% Backtested Accuracy
Analyst Views on MLSS
About MLSS
About the author
Milestone Scientific Launches CompuFlo Advisor Program to Boost Adoption
- Strategic Initiative Launched: Milestone Scientific launched the CompuFlo® Advisor Program on February 1, 2026, aimed at driving mainstream commercial adoption and increasing recurring disposable revenue to optimize long-term Medicare reimbursement rates.
- Target Market Defined: The program focuses on high-volume interventional pain and anesthesia practices within key Medicare Administrative Contractor jurisdictions, including Novitas, First Coast, Noridian, and Palmetto, marking the first phase of strategic execution across the U.S.
- Clinical Data Generation: By collaborating with Key Opinion Leaders, Milestone aims to generate 1,000 to 2,000 case submissions in the initial six months to transition CPT® code 0777T from Category III to Category I, which is expected to enhance commercial adoption and long-term revenue visibility.
- Robust Support Infrastructure: The company has deployed a strong commercial infrastructure and engaged industry veterans to provide real-time claims support and documentation guidance, ensuring the Advisor Program can deliver a scalable recurring revenue model to facilitate nationwide expansion.
Vanda Pharmaceuticals' NEREUS Receives FDA Approval, Shares Surge 17.5%
- FDA Approval: Vanda Pharmaceuticals' NEREUS (tradipitant) has received FDA approval for the prevention of motion-induced vomiting in adults, marking a significant advancement in the company's neuropharmaceutical portfolio and is expected to drive future sales growth.
- Stock Surge: Following the FDA approval announcement, Vanda's shares jumped 17.5% to $8.26 in pre-market trading, reflecting strong market confidence in the new drug's potential and likely attracting increased investor interest.
- Market Outlook: The approval of NEREUS not only opens new market opportunities for Vanda Pharmaceuticals but also enhances its market share in the competitive antiemetic drug sector, strengthening the company's long-term profitability prospects.
- Investor Confidence: This FDA approval boosts investor expectations for Vanda's future performance, potentially prompting more institutional investors to reassess their portfolios, further driving the stock price upward.
Benchmark Keeps Speculative Buy Rating on Milestone Scientific, Reduces Price Target to $1
Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders to stay updated on market movements.
Exclusive Content: The platform provides exclusive stories and insights generated by Benzinga reporters for its users.
Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, benefiting from shared intelligence.
Market Winning Tools: Benzinga Pro is designed to help traders win in the markets every day with accurate stock market intelligence.
RLX Technology Shares Rise 6%; Check Out 20 Stocks Making Moves in Premarket Trading
RLX Technology Inc Performance: RLX Technology's shares rose 6% to $2.47 in pre-market trading after reporting third-quarter earnings of 3 cents per share and $158.6 million in sales.
Notable Gainers: Cidara Therapeutics surged 92% to $203.50 following a significant ownership disclosure, while other companies like Binah Capital Group and Expion360 also saw substantial pre-market gains.
Significant Losers: TSS Inc experienced a 40.2% drop to $9.10 after reporting a year-over-year decline in financial results, with enVVeno Medical Corp and Nuvve Holding Corp also facing significant losses.
Market Overview: The pre-market trading session showed a mix of gains and losses among various stocks, reflecting varied financial performances and investor reactions to earnings reports.
Milestone Scientific (MLSS) Shares Surge More Than 35% in After-Hours Trading — Find Out the Reason
Stock Surge: Milestone Scientific Inc. (MLSS) shares rose 35.67% in after-hours trading to $0.52 following the release of its third-quarter results, which showed reduced costs and improved losses.
Cost Reduction and Losses: The company cut operating expenses by over $500,000, resulting in a 23% decrease in operating loss to approximately $1.1 million, while net loss narrowed to $1.2 million.
Mixed Revenue Performance: Third-quarter revenue slightly declined to $2.4 million, impacted by lower domestic dental sales, but overall revenue for the first nine months increased by 5% to $6.9 million due to growth in international markets.
Reimbursement Strategy: CEO Eric Hines highlighted progress in the company's reimbursement strategy, aiming to enhance adoption of its medical segment through improved Medicare payment rates and expanded commercial coverage.
Applied Therapeutics, Omeros, and Others Experience Significant Price Changes After Market Close
Milestone Scientific Inc. Earnings: Milestone Scientific's shares rose 36.10% after reporting a third-quarter net loss of $1.2 million, with revenue slightly down to $2.4 million due to weaker domestic dental sales but stronger international demand.
Applied Therapeutics Inc. Update: Applied Therapeutics saw a 14.78% increase in shares after narrowing its Q3 net loss to $19 million and announcing a meeting with the FDA to discuss the regulatory path for govorestat in Classic Galactosemia.
Omeros Corp. Financial Results: Omeros Corp. shares gained 20.54% following a Q3 net loss of $30.9 million, with an update on its Biologics License Application for narsoplimab and an extended FDA action date to December 2025.
The Oncology Institute Inc. Performance: The Oncology Institute's shares rose 19.48% after reporting a 36.7% increase in Q3 revenue to $136.6 million, while also raising its full-year revenue guidance to between $495 million and $505 million.
Milestone Scientific Launches CompuFlo Advisor Program to Boost Adoption
- Strategic Initiative Launched: Milestone Scientific launched the CompuFlo® Advisor Program on February 1, 2026, aimed at driving mainstream commercial adoption and increasing recurring disposable revenue to optimize long-term Medicare reimbursement rates.
- Target Market Defined: The program focuses on high-volume interventional pain and anesthesia practices within key Medicare Administrative Contractor jurisdictions, including Novitas, First Coast, Noridian, and Palmetto, marking the first phase of strategic execution across the U.S.
- Clinical Data Generation: By collaborating with Key Opinion Leaders, Milestone aims to generate 1,000 to 2,000 case submissions in the initial six months to transition CPT® code 0777T from Category III to Category I, which is expected to enhance commercial adoption and long-term revenue visibility.
- Robust Support Infrastructure: The company has deployed a strong commercial infrastructure and engaged industry veterans to provide real-time claims support and documentation guidance, ensuring the Advisor Program can deliver a scalable recurring revenue model to facilitate nationwide expansion.
Vanda Pharmaceuticals' NEREUS Receives FDA Approval, Shares Surge 17.5%
- FDA Approval: Vanda Pharmaceuticals' NEREUS (tradipitant) has received FDA approval for the prevention of motion-induced vomiting in adults, marking a significant advancement in the company's neuropharmaceutical portfolio and is expected to drive future sales growth.
- Stock Surge: Following the FDA approval announcement, Vanda's shares jumped 17.5% to $8.26 in pre-market trading, reflecting strong market confidence in the new drug's potential and likely attracting increased investor interest.
- Market Outlook: The approval of NEREUS not only opens new market opportunities for Vanda Pharmaceuticals but also enhances its market share in the competitive antiemetic drug sector, strengthening the company's long-term profitability prospects.
- Investor Confidence: This FDA approval boosts investor expectations for Vanda's future performance, potentially prompting more institutional investors to reassess their portfolios, further driving the stock price upward.
Benchmark Keeps Speculative Buy Rating on Milestone Scientific, Reduces Price Target to $1
Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders to stay updated on market movements.
Exclusive Content: The platform provides exclusive stories and insights generated by Benzinga reporters for its users.
Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, benefiting from shared intelligence.
Market Winning Tools: Benzinga Pro is designed to help traders win in the markets every day with accurate stock market intelligence.
RLX Technology Shares Rise 6%; Check Out 20 Stocks Making Moves in Premarket Trading
RLX Technology Inc Performance: RLX Technology's shares rose 6% to $2.47 in pre-market trading after reporting third-quarter earnings of 3 cents per share and $158.6 million in sales.
Notable Gainers: Cidara Therapeutics surged 92% to $203.50 following a significant ownership disclosure, while other companies like Binah Capital Group and Expion360 also saw substantial pre-market gains.
Significant Losers: TSS Inc experienced a 40.2% drop to $9.10 after reporting a year-over-year decline in financial results, with enVVeno Medical Corp and Nuvve Holding Corp also facing significant losses.
Market Overview: The pre-market trading session showed a mix of gains and losses among various stocks, reflecting varied financial performances and investor reactions to earnings reports.
Milestone Scientific (MLSS) Shares Surge More Than 35% in After-Hours Trading — Find Out the Reason
Stock Surge: Milestone Scientific Inc. (MLSS) shares rose 35.67% in after-hours trading to $0.52 following the release of its third-quarter results, which showed reduced costs and improved losses.
Cost Reduction and Losses: The company cut operating expenses by over $500,000, resulting in a 23% decrease in operating loss to approximately $1.1 million, while net loss narrowed to $1.2 million.
Mixed Revenue Performance: Third-quarter revenue slightly declined to $2.4 million, impacted by lower domestic dental sales, but overall revenue for the first nine months increased by 5% to $6.9 million due to growth in international markets.
Reimbursement Strategy: CEO Eric Hines highlighted progress in the company's reimbursement strategy, aiming to enhance adoption of its medical segment through improved Medicare payment rates and expanded commercial coverage.
Applied Therapeutics, Omeros, and Others Experience Significant Price Changes After Market Close
Milestone Scientific Inc. Earnings: Milestone Scientific's shares rose 36.10% after reporting a third-quarter net loss of $1.2 million, with revenue slightly down to $2.4 million due to weaker domestic dental sales but stronger international demand.
Applied Therapeutics Inc. Update: Applied Therapeutics saw a 14.78% increase in shares after narrowing its Q3 net loss to $19 million and announcing a meeting with the FDA to discuss the regulatory path for govorestat in Classic Galactosemia.
Omeros Corp. Financial Results: Omeros Corp. shares gained 20.54% following a Q3 net loss of $30.9 million, with an update on its Biologics License Application for narsoplimab and an extended FDA action date to December 2025.
The Oncology Institute Inc. Performance: The Oncology Institute's shares rose 19.48% after reporting a 36.7% increase in Q3 revenue to $136.6 million, while also raising its full-year revenue guidance to between $495 million and $505 million.
